

Anticonvulsants - pregabalin (LYRICA®)

Medical policy no. 72.60.00.57-1

Effective July 1, 2018

Medical necessity

| Drug | Medical Necessity |
|----------------------|--|
| pregabalin (LYRICA®) | LYRICA® may be considered medically necessary for any of the following diagnosis: 1. Epilepsy/convulsions 2. Diabetic peripheral neuropathy 3. Fibromyalgia 4. Neuropathic pain due to spinal cord injury 5. Postherpetic neuralgia |

Clinical policy:

| Clinical Criteria | |
|--------------------------------|--|
| Initial authorization criteria | ONE of the following: 1. Diagnosis of Epilepsy/convulsions 2. ALL of the following: a. Diagnosis of ONE of the following: i. Diabetic peripheral neuropathy 1) Dose ≤ 300mg/day ii. Fibromyalgia 1) Dose ≤ 450mg/day iii. Neuropathic pain due to spinal cord injury 1) Dose ≤ 600mg/day iv. Postherpetic neuralgia 1) Dose ≤ 600mg/day b. ONE of the following: i. Client has been stable on Lyrica (pregabalin) ii. History of failure, contraindication, or intolerance to gabapentin 1800mg/day for 4 weeks c. Client is greater than or equal to (≥) 12 years of age |
| Reauthorization criteria | ONE of the following: 1. Diagnosis of Epilepsy/convulsions 2. BOTH of the following: a. Dosage has not exceeded the above maximum limit for diagnosis |



| b. Documentation of positive clinical benefit |
|---|
| Approval for 12 months |

Dosage and quantity limits

| Diagnosis | Dose and Quantity Limits |
|-------------------------------------|-----------------------------------|
| Diabetic peripheral neuropathy | Maximum dose 300mg per day |
| | Quantity limit 3 capsules per day |
| Fibromyalgia | Maximum dose 450mg per day |
| | Quantity limit 3 capsules per day |
| Neuropathic pain due to spinal cord | Maximum dose 600mg per day |
| injury | Quantity limit 3 capsules per day |
| Postherpetic neuralgia | Maximum dose 600mg per day |
| | Quantity limit 3 capsules per day |

References

1. Product Information: LYRICA oral capsules, oral solution, pregabalin oral capsules, oral solution. Parke-Davis (per FDA), New York, NY, 2018.